Early diagnosis, regular monitoring feature in new call for Japanese health system overhaul
This article was originally published in Clinica
Two major foreign business groups in Japan have released a new White Paper on Health Policy that includes close to 200 proposals designed to improve the cost-efficiency of the Japanese healthcare system, labor productivity and ultimately economic growth.
You may also be interested in...
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.